In addition, co-mutation is common in NSCLC patients with EGFR mutations, and the efficacy of first-line TKI monotherapy in NSCLC patients with EGFR co-mutations is significantly worse than that in patients without co-mutations [9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.